Elevance Health (ELV) analyst forecast and price target
Analyst forecast
Consensus of 26 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $460.00 from $455.00 | Oct 12, 2026 |
| Barclays | Maintained | Overweight | $469.00 from $457.00 | Oct 7, 2026 |
| Leerink Partners | Maintained | Market Perform | $395.00 from $364.00 | Jul 17, 2026 |
| Baird | Maintained | Neutral | $393.00 from $331.00 | Jul 16, 2026 |
| Barclays | Maintained | Overweight | $457.00 from $480.00 | Jul 16, 2026 |
| Guggenheim | Maintained | Buy | $455.00 from $399.00 | Jul 16, 2026 |
| Wells Fargo | Maintained | Overweight | $473.00 from $492.00 | Jul 16, 2026 |
| RBC Capital | Maintained | Sector Perform | $424.00 from $439.00 | Jul 16, 2026 |
| Truist Securities | Maintained | Buy | $475.00 from $450.00 | Jul 14, 2026 |
| TD Cowen | Maintained | Buy | $465.00 from $400.00 | Jul 14, 2026 |
| Wells Fargo | Maintained | Overweight | $492.00 from $391.00 | Jul 13, 2026 |
| RBC Capital | Maintained | Sector Perform | $439.00 from $358.00 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $450.00 from $400.00 | Jul 7, 2026 |
| Bernstein | Maintained | Outperform | $482.00 from $424.00 | Jul 2, 2026 |
| JP Morgan | Maintained | Overweight | $476.00 from $411.00 | Jun 8, 2026 |
| Mizuho | Maintained | Outperform | $465.00 from $435.00 | Jun 8, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $404.00 from $352.00 | Jun 4, 2026 |
| B of A Securities | Maintained | Buy | $460.00 from $435.00 | Jun 4, 2026 |
| Truist Securities | Maintained | Buy | $450.00 from $375.00 | Jun 1, 2026 |
| Barclays | Maintained | Overweight | $480.00 from $408.00 | May 26, 2026 |
Frequently asked questions
What is the price target for ELV stock?
The average 12-month analyst price target for Elevance Health (ELV) is $435.67, with a high estimate of $473.00 and a low of $393.00, across 6 analysts.
Is ELV a buy, sell, or hold?
Analysts covering Elevance Health currently average a Buy rating: 16 buy, 10 hold and 0 sell, from 26 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ELV?
The average price target of $435.67 implies 1.77% upside from the last price of $428.09.
What is the latest analyst rating on ELV?
On Oct 12, 2026, Guggenheim maintained Elevance Health at Buy with a price target of $460.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.